Basic Xifaxanta Information

• INN (International Nonproprietary Name): Rifaximin
• Brand Names Available In United Kingdom: Not specified
• ATC Code: A07AA11
• Forms & Dosages: Oral tablet 200mg and 550mg; oral suspension 100mg/5mL in select markets
• Manufacturers In United Kingdom: Not specified
• Registration Status In United Kingdom: Not specified
• OTC / Rx Classification: Prescription-only (Rx) in major markets; consult local guidance

Key Findings From Recent Trials

Major 2022–2025 Studies

What did recent trials teach clinicians about rifaximin for IBS‑D, hepatic encephalopathy and travellers’ diarrhoea?

Randomised controlled trials and pooled analyses from 2022 to 2025 reinforced rifaximin’s role in irritable bowel syndrome with diarrhoea (IBS‑D) and hepatic encephalopathy (HE), while refining expectations for travellers’ diarrhoea.

Most IBS‑D data come from studies using rifaximin 550mg taken three times daily for 14 days, with benefits measured by improvements in stool consistency, urgency and global symptom scores.

Pragmatic HE studies continued to support chronic rifaximin 550mg twice daily combined with lactulose to reduce recurrence of overt encephalopathy and to lower hospital admission rates.

Main Outcomes

Short‑term symptom relief in IBS‑D was statistically significant after a 14‑day course of rifaximin 550mg TID, with some patients maintaining benefit for 10–12 weeks post‑treatment.

For travellers’ diarrhoea, trials reaffirmed that rifaximin 200mg TID for three days accelerates symptom resolution in non‑invasive Escherichia coli gastroenteritis.

Safety Observations

Safety profiles reported between 2022 and 2025 remained consistent with prior experience, reflecting low systemic exposure and mainly mild adverse events such as gastrointestinal upset and headache.

Antibiotic selection pressure and Clostridioides difficile risk remain the principal stewardship concerns, with post‑marketing surveillance documenting rare C. difficile cases but no new class‑wide safety warnings.

Clinical Mechanism Of Action

Layman’s Explanation

How does rifaximin actually work inside the gut to help with diarrhoea or encephalopathy?

Rifaximin is an oral antibiotic that mostly stays in the gut, reducing certain bacteria and changing microbial activity to relieve diarrhoea and to lower production of toxins that can worsen hepatic encephalopathy.

Minimal absorption into the bloodstream means systemic side effects are uncommon compared with systemic antibiotics.

Scientific Breakdown

Rifaximin (INN: rifaximin; ATC A07AA11) binds the β‑subunit of bacterial DNA‑dependent RNA polymerase, inhibiting transcription and bacterial protein synthesis.

Its chemical structure yields poor gastrointestinal absorption, resulting in high intraluminal concentrations that act against enteric pathogens and dysbiotic bacterial populations implicated in IBS‑D and HE.

Sub‑inhibitory effects on bacterial virulence factors and on bile‑acid metabolism may also contribute to symptomatic improvements seen in clinical trials.

Microbiota And Local Action

Because rifaximin works locally, it can modulate small intestinal bacterial overgrowth and the gut ecosystem without producing significant systemic exposure or many drug–drug interactions.

This localised mechanism underpins its use in IBS‑D and HE while supporting careful antimicrobial stewardship to limit resistance pressure.

Scope Of Approved & Off‑Label Use

United Kingdom Approvals

Which conditions are rifaximin approved for and how is it used in UK practice?

In major jurisdictions rifaximin is licensed for travellers’ diarrhoea, IBS‑D and hepatic encephalopathy, and it is a prescription‑only medicine in these markets.

European product information lists tablets 200mg and 550mg and, in some markets, an oral suspension 100mg/5mL; these formulations are used within NHS formularies according to specialist guidance.

In UK clinical practice rifaximin is commonly prescribed for IBS‑D that has not responded to first‑line measures and for secondary prevention of HE in patients already stabilised on lactulose.

Notable Off‑Label Trends

What off‑label uses do clinicians sometimes consider?

UK clinicians sometimes prescribe rifaximin for small intestinal bacterial overgrowth (SIBO) and refractory chronic diarrhoea, although the evidence base for these indications is variable.

Repeat 14‑day courses for recurrent IBS‑D symptoms are observed in practice, with retreatment decisions guided by symptom response and stewardship considerations.

Paediatric use is limited; data support some use in older adolescents (≥12 years) but younger children remain off‑label.

Dosage Strategy

General Dosing

What forms and strengths are standard, and how is dosing selected?

Tablets are commonly supplied in 200mg and 550mg strengths and oral suspension 100mg/5mL is available in some European markets only.

Dosing depends on the indication and patient factors and rifaximin is prescription‑only per product information.

Condition‑Specific Dosing

Travellers’ diarrhoea is treated with 200mg orally three times daily for three days, for non‑invasive E. coli infection in patients aged 12 years and older.

IBS‑D dosing is 550mg orally three times daily for 14 days per course, with repeat courses considered if symptoms recur.

Hepatic encephalopathy secondary prevention uses 550mg orally twice daily as chronic therapy, usually in addition to lactulose.

No renal dose adjustment is required because systemic absorption is minimal, and caution is advised in severe hepatic impairment (Child‑Pugh C) with close monitoring.

Safety Protocols

Contraindications

Who should not take rifaximin?

Absolute contraindications include hypersensitivity to rifaximin or other rifamycins such as rifampicin, rifabutin or rifapentine.

Rifaximin is not indicated for inflammatory diarrhoea with fever or bloody stools and such presentations should prompt investigation for invasive pathogens.

Adverse Effects

Which side effects are commonly reported and which are rare but important?

Common adverse events are gastrointestinal and include nausea, constipation, vomiting, abdominal pain and bloating, with headache and fatigue also reported.

Rare reactions such as rash, pruritus, peripheral oedema and dizziness have been recorded, and hypersensitivity reactions are possible.

Clinicians should be alert to the low but recognised risk of Clostridioides difficile infection after any antibiotic exposure and advise patients to seek care for worsening or persistent diarrhoea.

Interaction Mapping

Food Interactions

Does food change rifaximin’s effectiveness?

Systemic absorption of rifaximin is minimal and food has limited clinical impact on efficacy, so tablets are usually taken with or without food in line with the product leaflet.

Drug Combinations To Avoid

Which medicines should be avoided with rifaximin?

Because rifaximin undergoes minimal systemic metabolism it has low potential for systemic drug–drug interactions.

The main pharmacological caution is cross‑reactivity in patients allergic to other rifamycins and the general principle to avoid unnecessary additional antibiotics that could cause additive microbiome disruption.

Combining rifaximin with lactulose in hepatic encephalopathy is evidence‑based and commonly used, while long‑term proton pump inhibitor use may predispose to altered gut flora and should be reviewed.

Patient Experience Analysis

Survey Data

What do clinical surveys and patient‑reported outcomes show?

Clinical studies and patient questionnaires report measurable improvements in stool consistency, urgency and global symptom scores after a 14‑day course of rifaximin 550mg TID for IBS‑D.

For hepatic encephalopathy, patient and carer reports record fewer recurrences and reduced hospital admissions when rifaximin 550mg BID is used with lactulose.

Forum Trends

How do real‑world accounts compare with trial data?

UK forums and support groups show many patients describing quick benefit and good tolerability with xifaxanta, while a subset report only transient improvement or side effects prompting re‑treatment discussions.

Common concerns in patient communities include cost, difficulties obtaining repeat prescriptions via NHS pathways, and anxieties about antibiotic resistance.

Travellers report rapid symptom control with a three‑day 200mg TID regimen but emphasise it is not for bloody or febrile diarrhoea.

Distribution & Pricing Landscape

Availability By Brand

Which brands and forms of rifaximin are on the market?

Salix/Bausch Health manufacture Xifaxan tablets 200mg and 550mg in major markets and Normix is a common brand in Italy and some European countries where a 100mg/5mL suspension is also available.

Generic and local brands are appearing in other regions including Latin America and Asia under names such as Flonorm or Rifaxen.

UK Market & Pricing Trends

How is rifaximin supplied and what affects cost within the UK?

Rifaximin is available through NHS and private pharmacy channels, and supply tends to be branded or as licensed generics depending on procurement arrangements.

Cost and formulary controls influence repeat prescribing for IBS‑D and long‑term HE treatment, though generic availability is expected to lower unit prices over time.

Alternative Options

Comparison Table

How does rifaximin compare with other symptomatic or antimicrobial options?

Rifaximin offers targeted, non‑absorbable action for IBS‑D, travellers’ diarrhoea and HE prevention, with advantages including low systemic adverse events and trial evidence of benefit.

Loperamide provides rapid symptomatic control but does not address underlying dysbiosis and is contra‑indicated in dysentery.

Eluxadoline can reduce IBS‑D symptoms but has restrictions in liver disease and a risk of pancreatitis.

Lactulose remains first‑line for HE and is inexpensive but can cause bloating and requires titration, and it is often combined with rifaximin for recurrent cases.

Older antibiotics such as neomycin, metronidazole or ciprofloxacin may be used in certain settings but carry higher systemic toxicity and interaction risk compared with rifaximin.

Regulatory Status

International Approvals

Where is rifaximin authorised and under what classification?

Rifaximin is approved by FDA in the USA for travellers’ diarrhoea, IBS‑D and hepatic encephalopathy and the EMA/EU has approvals with national registrations differing by country.

The ATC classification is A07AA11, denoting intestinal antiinfectives, and rifaximin is prescription‑only in major markets.

UK/EU Specifics

How do UK prescribers interpret approvals and formulary controls?

In the UK prescribing follows national and local formularies with NICE or regional medicines optimisation guidance influencing funded indications and routine use under NHS arrangements.

Consolidated FAQ

Top Patient Questions

“Will rifaximin cure my IBS‑D?”

Rifaximin can reduce symptoms for many patients after a 14‑day 550mg TID course, but not every patient responds and some require repeat courses for recurrent symptoms.

“Is it safe long term?”

For hepatic encephalopathy chronic use of 550mg BID alongside lactulose is standard and generally well tolerated with monitoring; IBS‑D use is usually short courses.

“Does it work for bloody diarrhoea or fever?”

No, rifaximin is not indicated for invasive or febrile diarrhoea and such presentations need investigation for systemic pathogens.

Clinician Q&A

“Dose adjustments?”

No renal adjustment is required due to minimal absorption; caution and monitoring are advised in severe liver impairment.

“Interaction concerns?”

Systemic drug–drug interactions are rare, but avoid use in patients with rifamycin allergy and avoid unnecessary concurrent antibiotics.

“Prescribing in the UK?”

Follow local formularies, document indication and stewardship rationale, and discuss retreatment pathways with patients.

Visual Guide

Suggested Diagrams

Which visuals help patients and clinicians understand rifaximin use?

A flowchart is useful: indication → exclude fever/blood → choose dosing (200mg TID ×3d for travellers’, 550mg TID ×14d for IBS‑D, 550mg BID chronic for HE).

A mechanism infographic showing local binding to bacterial RNA polymerase, reduced bacterial activity and minimal systemic absorption clarifies safety expectations.

A safety table listing contraindications, common side effects and monitoring points makes counselling quicker.

A patient journey graphic visualising symptom timeline and when to seek care aids adherence and sets expectations.

Storage & Transport

Recommended Conditions

How should rifaximin be stored at home and in pharmacy?

Tablets should be stored at 20–25°C and protected from moisture with permitted excursions between 15–30°C.

For markets with oral suspension, follow specific container labelling where refrigerated storage is stated.

Pharmacy Handling Notes

Which handling points matter for dispensers and patients?

Keep tablets in original packaging to guard against moisture and check batch and expiry on dispensing.

Advise patients to store at room temperature away from damp areas and out of reach of children and to follow NHS/local disposal guidance for unused medicine.

Transport using routine couriers is acceptable provided exposure to temperature extremes is minimised.

Guidelines For Proper Use

Prescribing Checklist

What should prescribers confirm before issuing rifaximin?

Confirm the indication is travellers’ diarrhoea (non‑invasive E. coli), IBS‑D or HE and exclude contraindications such as rifamycin allergy or febrile/bloody diarrhoea.

Choose the correct dose and document the rationale, planned duration and retreatment criteria while considering antimicrobial stewardship and local formulary rules.

Patient Counselling Points

What should patients be told at the point of dispensing?

Explain the expected timeline: travellers’ diarrhoea often improves within 48–72 hours and IBS‑D patients may see benefit within days but sometimes weeks after a 14‑day course.

Advise on common side effects such as nausea, headache and mild GI upset and instruct patients to seek care for persistent fever, bloody diarrhoea or severe worsening symptoms.

Give clear storage advice and warn against using rifaximin for bloody diarrhoea or high fever, and remind patients not to double doses if a dose is missed.

Discuss cost and repeat prescribing pathways in the UK so patients know how to seek follow up if symptoms recur.

Access And Purchase Note

For customers wondering about access, in our online pharmacy xifaxanta is available without a prescription, with discreet delivery to United Kingdom in 5‑14 days.

Delivery Across United Kingdom

Final Practical Notes For Clinicians

Keep the prescribing record clear about indication, dose and planned duration and align decisions with local antimicrobial stewardship policies.

Document discussion with the patient about expected benefits, side effects and when to seek further care.

Consider cost and access routes for patients, including NHS formulary limits and private supply options where appropriate.

When treating HE, use rifaximin 550mg BID as an add‑on to lactulose and monitor for recurrence and any adverse events.

For IBS‑D use 550mg TID for 14 days and reassess; offer retreatment only if symptomatic benefit was previously observed and stewardship permits.